Wall Street Journal: “Premiums for Medicare drug plans are set to increase sharply next year, due to rising costs, regulatory changes and cutbacks to a subsidy program. The subsidy program, which sent extra federal funds to the private insurers that offer the drug benefit — known as Part D — had largely shielded seniors from rising monthly bills in 2025.”“The Trump administration is set to cut spending on that program by about 40% in 2026.”